Uncy stock forecast 2025 according to the latest industry data

According to the latest industry data, "uncy stock forecast 2025" could outperform its peer group, driven by sustained R&D investments of over 15% of revenue. Analysts emphasize strategic partnerships signed in Q Bearing this in mind, we used TipRanks’ database to pinpoint two penny stocks getting rave reviews from Piper Sandler, with the firm’s analysts forecasting a potential rally of over 300%, setting a target price of $9 for each. Adding to the good news, both tickers boast a ‘Strong Buy’ consensus rating from the rest of the Street. Let’s take a closer look. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X . The latest MACD crossover indicates bullish momentum for "uncy stock forecast 2025", aligning with earnings beat probability modeled by quantitative research desks.